Opioid pain management: Balancing risks and benefits

Drug Topics

Volumn 155, Issue 9, 2011, Pages 46-58

  Fudin, Jeffrey ^a,b,c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

^c American Academy of Pain Management   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLPIPERIDINE DERIVATIVE; ALFENTANIL; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; BENZODIAZEPINE DERIVATIVE; BENZOMORPHAN DERIVATIVE; BUPRENORPHINE; BUTORPHANOL; CODEINE; DELTA OPIATE RECEPTOR; DEXTROPROPOXYPHENE; DIPHENOXYLATE; DIPHENYLHEPTANE DERIVATIVE; FENTANYL; GABAPENTIN; KAPPA OPIATE RECEPTOR; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALBUPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMORPHONE; PHENANTHRENE DERIVATIVE; PREGABALIN; REMIFENTANIL; SUFENTANIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BONE PAIN; CHRONIC PAIN; CONNECTIVE TISSUE; CONNECTIVE TISSUE PAIN; CONSTIPATION; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG DEPENDENCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG RELEASE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; HUMAN; HYPERALGESIA; NAUSEA; NEUROPATHIC PAIN; PAIN; PRESCRIPTION; RESPIRATION DEPRESSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; UNITED STATES; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING;

EID: 80053178040     PISSN: 00126616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Chronic pain in America: roadblocks to relief. American Pain Society Website. Available at: http://www.ampainsoc.org/links/roadblocks. Study conducted by Roper Starch Worldwide, 1999. Accessed 7/12/2011.
2. What is the impact of untreated and undertreated pain? American Pain Society Website. Available at: http://www.ampainsoc.org/press/backgrounder.htm. Accessed 8/17/2011.
3. Committee on Advancing Pain Research, Care, and Education, Institute of Medicine. Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011. Available at: http://books.nap.edu/openbook.php?record_id=13172&page=260. Accessed 8/17/2011.
4. AAPM facts and figures on pain. American Academy of Pain Medicine Website. Available at: http://www.painmed.org/PatientCenter/Facts_on_Pain.aspx#burden. Accessed 8/17/2011.
5. Deandrea S, Montanari M, Mojo L, et al. Prevalence of undertreatment in cancer pain: A review of published literature. Ann Oncol. 2008;19:1985-1991.
6. Edwards CL, Fillingim RB, Keefe FR. Ethnicity and pain. Pain. 2001;94(2):133-137.
7. Brennan F, Carr DB, Cousins M. Pain management: A fundamental human right. Anesth Analg. 2007;105:205-221.
8. Morgan, JP. American opiophobia: Customary underutilization of opioid analgesics. Adv Alcohol Subst Abuse. 1985;5(1-2):163-173. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2870626. Accessed 8/17/2011.
9. Alliance of States with Prescription Monitoring Programs. Available at: http://www.pmpalliance.org/pdf/pmpstatusmap2011.pdf. Accessed 7/7/2011.
10. Ready LB, Edwards WT. Management of acute pain: A practical guide. Taskforce on acute pain. Seattle: IASP Publications; 1992.
11. Cousins MJ, Bridenbaugh PO, Carr DB, et al. Neural Blockade in Clinical Anesthesia and Pain Medicine. 4th ed. Philadelphia: Lippincott, Williams, & Wilkins; 2009.
12. Chou R, Fanciullo GJ, Fine, PG. Clinical guidelines for theuse of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
13. Koenig, HJ. Chronic pain: Biomedical and spiritual approaches. Binghamton, NY: The Hayworth Pastoral Press; 2003:149. Available at: http://books.google.com/books?id=YBBaK1UvKcMC&pg=PA149&dq=chronic+pain+anxiety+sleep&hl=en&ei=ufRFTt3eMaP40gHKsKCECA&sa=X&oi=book_result&ct=result&resnum=6&ved=0CFIQ6AEwBQ#v=onepage&q=chronic%20pain%20anxiety%20sleep&f=false. Accessed 8/17/2011.
14. The Joint Commission. Guidelines for pain assessment and management. Available at: http://www.painbalance.org/jcaho-pain-assessmentand-management-principles-776761232. Accessed 8/17/2011.
15. Zorn K, Fudin J. Treatment of neuropathic pain: The role of unique opioid agents. Prac Pain Mgmt. 2011;26-33.
16. Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Gilman AG., eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Columbus, OH: McGraw-Hill;1996.
17. Fudin J, Levasseur DJ, Passik, Kirsh KL, Coleman J. Chronic pain management with opioids in patients with past or current substance abuse problems. J Pharm Prac. 2003;16:291-308. Available at: http://www.paindr.com/2003%20ChronicPainMgmtSubstance-Abuse.pdf. Accessed 8/18/2011.
18. Copyright 2011 Jeffrey Fudin. Reprinted by permission
19. OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010.
20. Hardman JG, Limbird LE, Gilman AG., eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. Columbus, OH: McGraw-Hill;1996.
21. Duragesic (Fentanyl Transdermal System) [package insert]. Raritan, NJ: PriCara, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
22. Fudin J. Can fentanyl patches be replaced sooner to improve pain control? Medscape Today 1/11/2008. Available at: http://www.medscape.com/viewarticle/566115. Accessed 9/8/2011.
23. White PF. Use of patient-controlled analgesia for management of acute pain. JAMA.1988;259(2):243-247.
24. Woodall HE, Chiu A, Weissman DE. Opioid allergic reactions #175. J Palliat Med. 2008;11(5):776-777.
25. Max M, Lynch S, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992; 326:1250-1256. Available at: http://www.nejm.org/doi/full/10.1056/NEJM199205073261904#t=articleTop. Accessed 8/18/2011.
26. Zorn KE, Fudin J. Treatment of neuropathic pain: The role of unique opioid agents Prac Pain Manag. May 2011;26-33, 119. Available at: http://www.paindr.com/Opioid%20Nerve%20Pain_Fudin-ZORN.pdf. Accessed 8/18/2011
27. Prommer E. Levorphanol: The forgotten opioid. Supp Care Canc. 2007;15:259-264. Available at: http://www.paindr.com/Levorphanol%20forgotten%20opioid_2007.pdf. Accessed 8/18/2011.
28. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio? J Clin Oncol. 1998;16(10):3216-3221.
29. Mao J, Price D, Mayer D. Mechanisms of hyperalgesia and morphine tolerance: A current view of their possible interactions. Pain. 1995;62: 259-274.
30. Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part II. Psychosomatics. 2003;44:515-520.
31. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther. 1988;44:431-435.
32. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991;50:308-313.
33. Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and Smephenytoin. Clin Pharmacol Ther. 1992;51:388-397. (published erratum appears in Clin Pharmacol Ther. 1994;55:648).
34. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723.
35. Ereshefsky L; Riesenman C, Lam YWF. Antidepressant drug interactions and the cytochrome P450 system: The role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29:10-19. Available at: http://cat.inist.fr/?aModele=afficheN&cpsidt=2889071. Accessed 8/19/2011.
36. Virani A, Mailis, A, Shapiroa L, Sheara N. Drug interactions in human neuropathic pain pharmacotherapy. Pain. 1997;73:3-13.
37. Tristani L, Fudin J. Rational polypharmacy and pain medications in the elderly. Dannemiller Education Center. March, 2009. Available at: http://www.pain.com/sections/professional/articles/article.cfm?id=104. Accessed 8/19/2011.
38. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain. 1997;69:1-18. Available at: http://www.sciencedirect.com/science/article/pii/S0304395996032678. Accessed 8/19/2011.
39. Pergolizzi J, Alon, E, Baron R, et. al. Tapentadol in the management of chronic low back pain: A novel approach to a complex condition? J Pain Res. 2011:4:203-210. Available at: http://www.dovepress.com/tapentadol-in-the-management-of-chroniclow-back-pain-a-novel-approach-peer-reviewed-article-JPR. Accessed 8/19/2011.
40. Neurontin [package insert]. New York, NY: Parke-Davis, Division of Pfizer Inc.; 2010.
41. Effexor XR [package insert]. Philadelphia, PA: Wyeth Laboratories; 2010.
42. Cymbalta [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.
43. Savella [package insert]. St. Louis, MO: Forest Pharmaceuticals; 2009.
44. Amitriptyline [package insert]. Princeton, NJ: Sandoz Inc.; 2010.
45. Tofranil [package insert]. Hazelwood, MO: Mallinckrodt; 2009.
46. Loboz KK, Shenfield GM. Drug combinations and impaired renal function - the "triple whammy." Brit J Clin Pharmacol. 2005;59(2):239-243. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.0306-5251.2004.2188.x/full. Accessed 8/22/2011.
47. Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the "triple whammy." Med J Aust. 2000;172(4):184-185.
48. Aneja A, Farkouh ME. Adverse cardiovascular effects ofNSAIDs: Driven by blood pressure, or edema? Ther Adv Cardiovasc Dis. 2008;2(1):53-66.
49. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-infi ammatory drugs: Network meta-analysis. BMJ. 2011; 342:c7086. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21224324. Accessed 8/22/2011.
50. Chang CM, Liu PYY, Yang YHK, et al. Use of the Beers criteria to predict adverse drug reactions among fl rst-visit elderly outpatients. J Hum Pharmacol Drug Ther. 2005;25(6):831-838. Available at: http://pharmacotherapyjournal.org/doi/abs/10.1592/phco.2005.25.6.831?cookieSet=1. Accessed 8/22/2011.
51. Gourlay DL, Heit HA, Kaplan YH. Urine Drug Testing In Clinical Practice. The Art And Science Of Patient Care. 4th ed. Stamford, CT: Pharmacon Group; May 2010. Available at: http://www.familydocs.org/flles/UDTMonograph_for_web.pdf. Accessed 4/25/2011.
52. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: A literature review. Eur J Pain. 2007;11(5):490-518. Available at: http://www.sciencedirect.com/science/article/pii/S1090380106001297. Accessed 4/25/2011.
53. Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J. 2007;100(10):1028-1036.
54. Coderre TJ, Katz J, Vaccarinoc AL, et al. Contribution of central neuroplasticity to pathological pain: Review of clinical and experimental evidence. Pain. 1993;52(3):259-285. Available at: http://www.sciencedirect.com/science/article/pii/030439599390161H. Accessed 4/25/2011.
55. Dworkin, R. Which individuals with acute pain are most likely to develop a chronic pain syndrome? J Pain. 1997;6(2):127-136.
56. Fudin J, Levasseur DJ, Passik SD, Kirsh KL, Coleman J. Chronic pain management with opioids in patients with past or current substance abuse problems. J Phar Prac. 2003;16;4:291-308.
57. Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain. 2010;11(7):602-611. Available at: http://www.sciencedirect.com/science/article/pii/S1526590010003299. Accessed 8/22/2011.
58. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheum Rep. 2008;10(1):11-18.